CSI Market
Sign In | Register

Alpine Immune Sciences Inc (ALPN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ALPN Annual Cash Flow →
A period-by-period view of cash flow from Alpine Immune Sciences Inc to Mar 31 2023 helps clarify how Mar 31 2024's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
3 Months 		(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income-17.92
Depreciation & amortization0.15
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Bargain Purchase, Gain Recognized, Amount0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation3.99
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Increase Decrease In Accrued Direct Program-
Increase Decrease In Contract With Customer Liability-6.99
Increase Decrease In Right Of Use Asset0.19
Conversion Of Stock Amount Converted-
Issuance Of Debt Discount-
Income taxes0.00
Realized Investment Gains (Losses), Total-0.02
Increase (Decrease) in Accounts Receivable0.12
Increase (Decrease) in Accounts Payable and Accrued Liabilities-3.82
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.41
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.99
Discontinued operations0.00
Net Cash flow from Operating Activities-27.69
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities72.85
Payments to Acquire Available-for-sale Securities, Debt-75.39
Real Estate Investments0.00
Cash And Cash Equivalents Acquired From Acquisition-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-2.56
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock19.36
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Exercise Of Stock Options And Common Stock Warrants-
Proceeds From Issuance Of Common Stock In Collaborative Arrangement-
Adjustments To Stock Offering Costs-0.01
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities19.35
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-27.71
Total Cash Flow-10.91
4 historic quarters locked

Sign in to unlock the full Alpine Immune Sciences Inc cash flow history.

Sign In Create Free Account

About Alpine Immune Sciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001626199-24-000064

Figures are derived from filed reports and may be restated. Historical data is subject to revision.